Circulating tumor DNA (ctDNA)(liquid biopsies) can help monitor cancer progression, detect residual cancer after treatment, and identify genetic changes within cancer cells that could affect treatment response. Author Ben Ho Park, MD, PhD, of the Vanderbilt-Ingram Cancer Center discusses current evidence regarding use of liquid biopsies in management of cancer with JAMA Deputy Editor Mary McGrae McDermott, MD.

Related Content:

• Liquid Biopsies for Cancer
• Applications of Liquid Biopsy for Surgical Patients With Cancer